ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NAMS vs MBX // RSI-14 & 200D SMA MOMENTUM

NewAmsterdam Pharma Company N.V. (NASDAQ) VS. MBX Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: NAMS 1 — MBX 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MBX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NAMS VS. MBX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NAMS MBX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -26.40% -8.60 MBX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -5.96% -3.12% -2.84 MBX /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -50.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 15.94 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 NAMS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 40.7 53.8 -13.13 MBX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.48B $2.63B -$145.1M MBX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NAMS REV MBX REV NAMS GROSS % MBX GROSS % NAMS FCF MBX FCF
FY 2025 $22.5M $0 — — -$147.8M -$81.9M
FY 2024 $45.6M $0 — — -$158.6M -$55.6M
FY 2023 $14.1M $0 — — -$141.2M -$32.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NAMS // BETA —
MBX // BETA —